In Brief: FDA ingrown toenail drug "feedback" meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA ingrown toenail drug "feedback" meeting: With Schering- Plough about addition of sodium sulfide 1% to the ingrown toenail relief OTC drug monograph will be held Jan. 20 at the request of Schering-Plough, which markets Dr. Scholl's foot care products. The company petitioned the agency for the monograph amendment in May 1994; FDA has raised concerns about the ingredient's safety. Schering-Plough Scientific and Regulatory Affairs Senior VP John Clayton, PhD, and Clinical Research/Regulatory Affairs VP Ronald Garutti, MD, will attend. The meeting will take place at 9201 Corporate Blvd., S200, Rockville, Md., starting at 9:30 a.m. For more information on the meeting, contact FDA's Melvin Lessing at (301) 827-2271...